286 related articles for article (PubMed ID: 18338334)
21. Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells.
Paju A; Hotakainen K; Cao Y; Laurila T; Gadaleanu V; Hemminki A; Stenman UH; Bjartell A
Eur Urol; 2007 Dec; 52(6):1670-9. PubMed ID: 17306443
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemical analysis of Bin1/Amphiphysin II in human tissues: diverse sites of nuclear expression and losses in prostate cancer.
DuHadaway JB; Lynch FJ; Brisbay S; Bueso-Ramos C; Troncoso P; McDonnell T; Prendergast GC
J Cell Biochem; 2003 Feb; 88(3):635-42. PubMed ID: 12532338
[TBL] [Abstract][Full Text] [Related]
23. Hepsin immunohistochemical expression in prostate cancer in relation to Gleason's grade and serum prostate specific antigen.
Goel MM; Agrawal D; Natu SM; Goel A
Indian J Pathol Microbiol; 2011; 54(3):476-81. PubMed ID: 21934206
[TBL] [Abstract][Full Text] [Related]
24. Genetic upregulation of matriptase-2 reduces the aggressiveness of prostate cancer cells in vitro and in vivo and affects FAK and paxillin localisation.
Sanders AJ; Parr C; Martin TA; Lane J; Mason MD; Jiang WG
J Cell Physiol; 2008 Sep; 216(3):780-9. PubMed ID: 18449907
[TBL] [Abstract][Full Text] [Related]
25. Androgen-Induced TMPRSS2 Activates Matriptase and Promotes Extracellular Matrix Degradation, Prostate Cancer Cell Invasion, Tumor Growth, and Metastasis.
Ko CJ; Huang CC; Lin HY; Juan CP; Lan SW; Shyu HY; Wu SR; Hsiao PW; Huang HP; Shun CT; Lee MS
Cancer Res; 2015 Jul; 75(14):2949-60. PubMed ID: 26018085
[TBL] [Abstract][Full Text] [Related]
26. Expression profiling reveals hepsin overexpression in prostate cancer.
Magee JA; Araki T; Patil S; Ehrig T; True L; Humphrey PA; Catalona WJ; Watson MA; Milbrandt J
Cancer Res; 2001 Aug; 61(15):5692-6. PubMed ID: 11479199
[TBL] [Abstract][Full Text] [Related]
27. Expression of the serine protease hepsin and clinical outcome of human endometrial cancer.
Matsuo T; Nakamura K; Takamoto N; Kodama J; Hongo A; Abrzua F; Nasu Y; Kumon H; Hiramatsu Y
Anticancer Res; 2008; 28(1A):159-64. PubMed ID: 18383840
[TBL] [Abstract][Full Text] [Related]
28. Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer.
Winnes M; Lissbrant E; Damber JE; Stenman G
Oncol Rep; 2007 May; 17(5):1033-6. PubMed ID: 17390040
[TBL] [Abstract][Full Text] [Related]
29. Two unique novel prostate-specific and androgen-regulated fusion partners of ETV4 in prostate cancer.
Hermans KG; Bressers AA; van der Korput HA; Dits NF; Jenster G; Trapman J
Cancer Res; 2008 May; 68(9):3094-8. PubMed ID: 18451133
[TBL] [Abstract][Full Text] [Related]
30. Pegylated kunitz domain inhibitor suppresses hepsin-mediated invasive tumor growth and metastasis.
Li W; Wang BE; Moran P; Lipari T; Ganesan R; Corpuz R; Ludlam MJ; Gogineni A; Koeppen H; Bunting S; Gao WQ; Kirchhofer D
Cancer Res; 2009 Nov; 69(21):8395-402. PubMed ID: 19843851
[TBL] [Abstract][Full Text] [Related]
31. [Frequency and transcript variant analysis of gene fusions between TMPRSS2 and ETS transcription factor genes in prostate cancer].
Dai MJ; Chen LL; Zheng YB; Chen W; Tao ZH; Weng ZL; Wu XL; Li CD; Chen ZG; Chen XD; Shi SB
Zhonghua Yi Xue Za Zhi; 2008 Mar; 88(10):669-73. PubMed ID: 18642766
[TBL] [Abstract][Full Text] [Related]
32. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases.
Mehra R; Han B; Tomlins SA; Wang L; Menon A; Wasco MJ; Shen R; Montie JE; Chinnaiyan AM; Shah RB
Cancer Res; 2007 Sep; 67(17):7991-5. PubMed ID: 17804708
[TBL] [Abstract][Full Text] [Related]
33. Low claudin expression is associated with high Gleason grade in prostate adenocarcinoma.
Väre P; Loikkanen I; Hirvikoski P; Vaarala MH; Soini Y
Oncol Rep; 2008 Jan; 19(1):25-31. PubMed ID: 18097572
[TBL] [Abstract][Full Text] [Related]
34. Compartmentalized expression of kallikrein 4 (KLK4/hK4) isoforms in prostate cancer: nuclear, cytoplasmic and secreted forms.
Dong Y; Bui LT; Odorico DM; Tan OL; Myers SA; Samaratunga H; Gardiner RA; Clements JA
Endocr Relat Cancer; 2005 Dec; 12(4):875-89. PubMed ID: 16322328
[TBL] [Abstract][Full Text] [Related]
35. The expression of pluripotency marker Oct 3/4 in prostate cancer and benign prostate hyperplasia.
Monsef N; Soller M; Isaksson M; Abrahamsson PA; Panagopoulos I
Prostate; 2009 Jun; 69(9):909-16. PubMed ID: 19274762
[TBL] [Abstract][Full Text] [Related]
36. Genome-wide linkage analysis of TMPRSS2-ERG fusion in familial prostate cancer.
Hofer MD; Kuefer R; Maier C; Herkommer K; Perner S; Demichelis F; Paiss T; Vogel W; Rubin MA; Hoegel J
Cancer Res; 2009 Jan; 69(2):640-6. PubMed ID: 19147579
[TBL] [Abstract][Full Text] [Related]
37. KLK31P is a novel androgen regulated and transcribed pseudogene of kallikreins that is expressed at lower levels in prostate cancer cells than in normal prostate cells.
Lu W; Zhou D; Glusman G; Utleg AG; White JT; Nelson PS; Vasicek TJ; Hood L; Lin B
Prostate; 2006 Jun; 66(9):936-44. PubMed ID: 16541416
[TBL] [Abstract][Full Text] [Related]
38. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
Ramberg H; Eide T; Krobert KA; Levy FO; Dizeyi N; Bjartell AS; Abrahamsson PA; Taskén KA
Prostate; 2008 Jul; 68(10):1133-42. PubMed ID: 18454446
[TBL] [Abstract][Full Text] [Related]
39. Increased PAK6 expression in prostate cancer and identification of PAK6 associated proteins.
Kaur R; Yuan X; Lu ML; Balk SP
Prostate; 2008 Oct; 68(14):1510-6. PubMed ID: 18642328
[TBL] [Abstract][Full Text] [Related]
40. Molecular cloning and expression of a variant form of hippostasin/KLK11 in prostate.
Nakamura T; Mitsui S; Okui A; Miki T; Yamaguchi N
Prostate; 2003 Mar; 54(4):299-305. PubMed ID: 12539228
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
